Advanced Search

Oncology & Hematology Coding Alert

Coding Tips:

Follow These 3 Steps To Banish The Blues For Blinatumomab Claims

Published on Fri Apr 17, 2015

Check with payer for reimbursement and do not miss the pre-medications. Blinatunomab (Blincyto TM) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  Submitting a claim for blinatumomab can leave you confused. Without a definitive code for blinatumomab, you will have to ensure you submit the best applicable code to strengthen your [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All